Journal of Clinical Oncology, Vol 12, 2094-2101, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study

G Gasparini, O Caffo, S Barni, L Frontini, A Testolin, RB Guglielmi and G Ambrosini
Department of Radiotherapy and Oncology, St Bortolo Medical Center, Vicenza, Italy.

PURPOSE: To evaluate the efficacy and toxicity of single-agent vinorelbine (VNB), a semisynthetic vinca alkaloid, in patients with breast cancer previously treated with other chemotherapeutic regimens for metastatic disease. PATIENTS AND METHODS: Sixty-seven of 70 patients with assessable disease entered onto the study were assessable. The main characteristics were as follows: median age, 60 years (range, 41 to 77); median performance status (PS; Karnofsky score), 90 (range, 60 to 100); and number of previous chemotherapeutic regimens given--one in 17, two in 27, three in eight, four in two, and five in one patient. The dominant sites of metastasis were viscera in 40, bone in 16, and soft tissues in 11 patients. VNB was administered beginning with the dose of 20 mg/m2 by 60-minute intravenous (iv) infusion weekly, with a dose escalation up to 25 mg/m2 if the first four courses were well tolerated. The treatment was continued until disease progression. RESULTS: Overall, 845 courses of VNB were given (median, 10; range, eight to 33). Objective responses were as follows: complete response (CR) in three (4.5%), partial response (PR) in 21 (31.2%), stable disease (SD) in 20 (30%), and progressive disease (PD) in 23 patients (34.3%). Twenty-four of 67 assessable patients obtained a major objective response (CR or PR, 36%; 95% confidence interval [Cl], 24% to 47%). Thirty-three percent of patients had a > or = 33% reduction of dose-intensity (DI). The median time to progression was 18 weeks. The drug was active in patients pretreated with either cyclophosphamide, methotrexate, and fluorouracil (CMF) or anthracyclines. The most relevant toxicity observed was myelosuppression: 17 (25%) and 19 patients (28%) had World Health Organization grade III, and six (9%) and six patients (9%) had grade IV leukopenia and granulocytopenia, respectively; two (3%) and two patients (3%) had grade III and IV anemia, respectively. Nonhematologic toxicities were phlebitis (grade II or III in 15 patients), alopecia (grade I or II in 16), nausea and vomiting (grade II or III in 15), diarrhea (grade II in two), constipation (grade II or III in 16), stomatitis (grade II or III in 13), peripheral neuropathy (grade II in seven), and asthenia (grade II in five). CONCLUSION: This study shows that VNB is an effective and well-tolerated agent in pretreated patients with advanced breast cancer. This drug does not seem to present cross-resistance with previous CMF or anthracycline regimens. Future clinical trials should be designed to prove whether the inclusion of VNB in combination chemotherapy regimens, or whether an enhancement of its dose-intensity using bone marrow growth factors, is able to improve further the efficacy of this drug in breast carcinoma.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. R. James, J. E. Quinn, P. B. Mullan, P. G. Johnston, and D. P. Harkin BRCA1, a Potential Predictive Biomarker in the Treatment of Breast Cancer Oncologist, February 1, 2007; 12(2): 142 - 150. [Abstract] [Full Text] [PDF]

				A. Hamilton and G. Hortobagyi Chemotherapy: What Progress in the Last 5 Years? J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775. [Full Text] [PDF]

				R. D. Kennedy, J. E. Quinn, P. B. Mullan, P. G. Johnston, and D. P. Harkin The Role of BRCA1 in the Cellular Response to Chemotherapy J Natl Cancer Inst, November 17, 2004; 96(22): 1659 - 1668. [Abstract] [Full Text] [PDF]

				M. D. Pegram, G. E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras, and D. J. Slamon Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer J Natl Cancer Inst, May 19, 2004; 96(10): 739 - 749. [Abstract] [Full Text] [PDF]

				J. P. Braybrooke, N. C. Levitt, S. Joel, T. Davis, S. Madhusudan, H. Turley, S. Wilner, A. L. Harris, and D. C. Talbot Pharmacokinetic Study of Cisplatin and Infusional Etoposide Phosphate in Advanced Breast Cancer with Correlation of Response to Topoisomerase II{alpha} Expression Clin. Cancer Res., October 15, 2003; 9(13): 4682 - 4688. [Abstract] [Full Text] [PDF]

				M. Jahanzeb, J. E. Mortimer, F. Yunus, D. H. Irwin, J. Speyer, A. J. Koletsky, P. Klein, T. Sabir, and L. Kronish Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer Oncologist, October 1, 2002; 7(5): 410 - 417. [Abstract] [Full Text] [PDF]

				H. J. Burstein, I. Kuter, S. M. Campos, R. S. Gelman, L. Tribou, L. M. Parker, J. Manola, J. Younger, U. Matulonis, C. A. Bunnell, et al. Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer J. Clin. Oncol., May 15, 2001; 19(10): 2722 - 2730. [Abstract] [Full Text] [PDF]

				A. Berruti, P. Sperone, A. Bottini, G. Gorzegno, V. Lorusso, A. Brunelli, M. Botta, M. Tampellini, M. Donadio, S. Mancarella, et al. Phase II Study of Vinorelbine With Protracted Fluorouracil Infusion as a Second- or Third-Line Approach for Advanced Breast Cancer Patients Previously Treated With Anthracyclines J. Clin. Oncol., October 19, 2000; 18(19): 3370 - 3377. [Abstract] [Full Text] [PDF]

				B. Norris, K. I. Pritchard, K. James, J. Myles, K. Bennett, S. Marlin, J. Skillings, B. Findlay, T. Vandenberg, P. Goss, et al. Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8 J. Clin. Oncol., June 12, 2000; 18(12): 2385 - 2394. [Abstract] [Full Text] [PDF]

				J. E. Groopman and L. M. Itri Chemotherapy-Induced Anemia in Adults: Incidence and Treatment J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634. [Abstract] [Full Text] [PDF]

				G. K. Ellis, J. R. Gralow, H. I. Pierce, M. A. Williams, and R. B. Livingston Infusional Paclitaxel and Weekly Vinorelbine Chemotherapy With Concurrent Filgrastim for Metastatic Breast Cancer: High Complete Response Rate in a Phase I-II Study of Doxorubicin-Treated Patients J. Clin. Oncol., May 1, 1999; 17(5): 1407 - 1407. [Abstract] [Full Text] [PDF]

				C. L. Vogel and J.-M. Nabholtz Monotherapy of Metastatic Breast Cancer: A Review of Newer Agents Oncologist, February 1, 1999; 4(1): 17 - 33. [Abstract] [Full Text]